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had a benign pathology, six (0.8%) were 
directly infiltrated by the tumour and 26 
(2.7%) were metastatic. For both benign and 
metastatic ipsilateral adrenal pathology, CT 
had sensitivity, specificity and positive/
negative predictive values of 47%, 99%, 73% 
and 96%, respectively. Of 29 contralateral 
glands removed because of suspicious CT 
findings (15 at diagnosis of renal cancer, 
14 during the follow-up) there was no 
abnormality in one (3.4%), a benign pathology 
in seven (24%) and a metastasis in 21 (72%). 
Thus there were 32 synchronous (incidence 
2.7%; ipsilateral to the renal tumour in 24, 
contralateral in six and bilateral in two), 
and 13 metachronous adrenal metastases 
(incidence 1.0%; contralateral in 11 
and bilateral in two). The metachronous 
metastases were diagnosed at a mean (range) 
interval of 30.6 (8–73) months after renal 
surgery. No ipsilateral adrenal metastases 
were discovered at diagnosis or during the 
follow-up in the 382 patients with an organ-




4 cm in diameter. 
Twenty-seven patients with an isolated 
adrenal metastasis (synchronous in 14, 









 0.001) better survival 
than the 18 (all synchronous) with multiple 
sites of metastatic disease. In particular, there 
was long-term survival (mean 83 months) 





Sparing the ipsilateral adrenal is advisable 




4 cm in diameter; clinical local staging of 
renal cancer is the best predictor of the risk of 
adrenal metastasis. Conversely, CT had good 
diagnostic ability for the contralateral adrenal 
gland, especially during the follow-up. Some 
patients with isolated adrenal metastasis 
could be treated by metastasectomy, with 
long-term survival free of disease and 
confirming that, even if in a few and 
unselectable patients, removing all the 
neoplastic bulk can be curative. Nevertheless, 
the high rate of relapse underlines the need 
for an effective systemic therapy, and more so 
for widespread metastatic disease that 
currently cannot be cured.
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To report, in a retrospective study, the 
diagnostic problems and oncological results 
of surgery in patients with either synchronous 
or metachronous adrenal metastasis, which 





Of 1179 patients treated for renal cancer 
between 1987 and 2003, 914 had renal 
surgery with concomitant ipsilateral 
adrenalectomy (routinely in 875 and for 
abnormal findings on computed tomography, 
CT, in 39) and 15 contralateral adrenalectomy 
(all after suspicious findings on CT). During 
the follow-up after renal surgery, another 14 
patients had adrenalectomy for CT evidence 
of an abnormal adrenal gland, contralateral 





Of 914 ipsilateral adrenal glands removed 
during renal surgery, 854 (93.5%) were 




RCC can metastasize to practically all 
organs, following routes of spread and 
patterns that are not yet fully understood. 
Adrenal metastasis is a good example, 
as it can be synchronous or metachronous 
to the renal neoplasm, ipsilateral, 
contralateral or bilateral, solitary or part 
of a diffuse metastatic disease. In the 
present retrospective study we report 
the diagnostic problems and results 
of surgery in patients with either 





Between January 1987 and December 2003, 
1179 consecutive patients with either uni- 
(1136) or bilateral (43) RCC were treated 
surgically (497 women and 696 men; mean 
age 61.5 years, range 20.6–94.9), during 1193 
surgical procedures. During the staging of 
the renal mass, CT detected some adrenal 
abnormalities (enlarged diameter, irregular 
morphology, heterogeneous density, 
contiguous infiltration by the neoplasm) in 48 
patients, ipsilateral to the renal neoplasm in 
33, contralateral in nine and bilateral in six, 
giving 54 suspicious adrenal units.
A radical nephrectomy with concomitant 
ipsilateral adrenalectomy was performed when 
preoperative assessments showed an adrenal 
abnormality, or routinely if the renal tumour 
was ineligible for nephron-sparing surgery. 
However, in a few patients at high surgical risk 
or with contralateral adrenal disease, the 
sparing of the ipsilateral adrenal gland was 
preferred if no anomalies were apparent and if 
the renal neoplasm did not involve the upper 
pole. Ipsilateral adrenalectomy was not usual 
during elective or imperative nephron-sparing 
surgery, unless adrenal pathology was 
suspected and a metastasis was excluded by 
immediate histological examination. Table 1 
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shows the procedures used with and with no 
ipsilateral adrenalectomy. A contralateral 
adrenalectomy was done only if there was a 
suspicion on preoperative imaging. Thus, an 
ipsilateral adrenalectomy accompanied renal 
surgery in 914 patients, 875 with normal and 
39 with abnormal CT findings, and a 
contralateral adrenalectomy in 15, all with 
suspicious CT results.
All the patients treated for RCC in our 
department are monitored indefinitely by 
periodic clinical and radiological (chest X-ray, 
abdominal ultrasonography and/or CT) 
evaluations. The mean (range) follow-up for 
the entire group was 49.6 (12–252) months. 
During the follow-up, an adrenal mass with 




3.5 cm, growth with time, irregular margins, 
heterogeneous density, presence of 





units, and rapid contrast medium wash-out) 
was detected in 14 asymptomatic patients. 
The lesion was contralateral to the side of 
previous kidney surgery in 12 patients and 
bilateral in the other two.
The RCC was staged using the TNM 2002 
system and therefore cases with direct 
adrenal invasion (stage pT3a) were not 
considered as metastatic. The histological 
subtypes were all determined using the 
Heidelberg classification [1].
The Kaplan-Meier method was used for the 
survival analysis, with the log-rank test to 
compare survival rates between different 








 0.05). The survival 
time was calculated from the diagnosis of 
adrenal metastasis for both synchronous and 
metachronous metastasis (i.e. excluding the 
interval between the diagnosis of kidney 
cancer and metastasis), so that we could 
compare groups of patients with oncological 
features (appearance of adrenal metastasis) 




Of 914 adrenal glands ipsilateral to RCC, 854 
were normal on pathological examination 
(93.5%, 844 with negative and 10 with 
positive preoperative CT), 28 had a benign 
pathology (3.0%, 17 with negative and 11 
with positive CT findings), 26 had a metastasis 
(2.7%, nine with negative and 17 with positive 
CT findings) and six had a neoplastic 
infiltration with a contiguous extension of 
RCC (0.8%, five with negative and one with 
positive CT). Thus, for diagnosing the 
pathology (both benign and metastatic) of the 
ipsilateral adrenal gland, CT had a sensitivity, 
specificity, positive and negative predictive 
values of 47%, 99%, 73% and 96%, 
respectively. Of 15 adrenal units removed 
contralateral to the renal surgery because of 
CT findings, there was no abnormality in one, 
benign pathology in six and a metastasis in 
eight.
Overall, 32 patients had a synchronous 
adrenal metastasis (21 men and 10 women, 
mean age 60 years, range 36–80), ipsilateral 
to the RCC in 24, contralateral in six and 
bilateral in two. In these patients the renal 
tumour affected the upper pole, either 
exclusively or with wider involvement of the 
organ, in 81%, 17% and all the ipsilateral, 
contralateral and bilateral cases, respectively; 
the respective mean (range) diameter of the 
renal neoplasm was 9.9 (5–20), 7.3 (4–9) 
and 9 (8–10) cm, and that of the adrenal 
metastasis was 2.7 (0.5–9), 4 (1.5–7) and 
5 (4–6) cm. In the nine cases of ipsilateral 
metastasis with a negative preoperative CT, 
the mean diameter of the adrenal mass was 
1.4 (0.5–3.2) cm. The histological examination 
of the renal neoplasm showed conventional 
RCC in 30 patients (three with sarcomatoid 
aspects), i.e. 2.9% of the 1011 conventional 
RCC treated, and a papillary carcinoma in two, 
i.e. 2.7% of the 74 RCC of the same histology. 
The histological subtype of the adrenal 
metastasis was always concordant with that 
of the renal neoplasm.
Data on the loco-regional staging of renal 
cancer (i.e. without considering distant 
metastasis) in patients with synchronous 
metastasis are reported in Table 2: notably, in 





4 cm in diameter. The pathological 
findings of the 16 adrenal units detected by CT 
in 14 patients during the follow-up showed a 
benign pathology in one and a metastasis in 13 
(eight men and five women, mean age 64 years, 
range 42–82), contralateral to the previous 
neoplasm in 11 and bilateral in two. The RCC 
was treated with nephroadrenalectomy in nine 
of the 13 patients, whereas an adrenal-sparing 
nephrectomy was used in the other four 
(including the two with bilateral metastases). 
At the time of renal surgery a conventional 
RCC, with a mean diameter of 9 (1–17) cm, 
with no distant metastasis (stage I in three, 
stage III in 10) was diagnosed. The mean 
diameter of the metachronous adrenal 
metastasis was 3.6 (1–6.5) cm. The median 
interval between treating RCC and the 
diagnosis of adrenal metastasis was 
30.6 (8–73) months.
After complete staging (abdomen, thorax, 
brain CT, and a bone scan), of the 32 patients 
with a synchronous adrenal metastasis, 14 
had an isolated metastasis to the adrenal 
while the other 18 had multiple-site 
metastatic disease, eligible for surgical, 
medical and/or radiation therapy in eight and 
for only palliative therapy in 10. This group 





Surgical options and 
pathological staging in 








TotalNSS Nephrectomy NSS Nephrectomy
I 219 41 5 392 657
II 1 4 1 85 91
III 9 8 1 267 285
IV – 3 – 157 159







Loco-regional staging of 
kidney cancer in patients 
with a synchronous adrenal 
metastasis.
 
Staging Ipsilateral Contralateral Bilateral










4 cm 2 2 0
Invasion of perirenal tissues
or venous involvement
12 4 1
Invasion of other organs 2 0 1
Lymph node metastasis 8 0 0
 








At present, of 14 patients with a solitary 
metastasis to the adrenal gland, four are 
alive and free from disease at a mean of 
99 months after surgery, two died from 
causes unrelated to kidney cancer at 3 and 
64 months, while the other eight had a 
relapse at a mean interval of 22.9 (5–57)  
months after surgery. In three of the 
last eight patients a second metastasectomy 
was performed (lung, contralateral adrenal 
gland, bone) while for the other five no 
therapy was considered. Two of the 
patients who had a second metastasectomy 
(lung and adrenal gland) died from other 
causes at a mean of 58 months after the 
second metastasectomy and 110 months 
after the previous adrenalectomy; the other 
six patients died at a mean of 15.1 months 
after adrenalectomy.
The eight patients with multiple metastases 
treated with curative intent relapsed 
at a mean of 10.2 (2–35) months after 
adrenalectomy, and either died or have 
incurable progression at a mean of 19.4 
(2–60) months after adrenalectomy. The 
remaining 10 patients with diffuse metastatic 
disease but ineligible for any curative 
treatment either progressed or died at a mean 
of 15.4 (2–60) months.
Patients with an isolated metastasis survived 
significantly longer than those with multiple 
















 0.001); there were no significant 
differences in survival time between patients 
with multiple metastases who received or did 


















The 13 patients with a metachronous adrenal 
metastasis were monitored for a median of 
50.5 (12–125) months; in all there were no 
other apparent relapses at a complete re-
staging (abdomen-thorax-brain CT, bone 
scan). Only four patients (one still alive and 
three dead from other causes) had no clinical 
evidence of further progression of the disease 
at a mean of 36.8 (12–65) months after 
adrenalectomy.
The other nine patients had progression at a 
mean of 33.9 (3–121) months; in three a 
second metastasectomy was feasible 
(contralateral kidney and renal fossa, bone, 
liver) while in the other six no curative 
treatment was attempted. To date these nine 
patients are either dead (seven) or have 
progression (two) at a mean of 57.3 
(5–125) months after adrenalectomy, with 
a mean survival time from relapse after 
adrenalectomy of 45.8 months in the three 
surgically treated patients and 5.6 months in 
the six untreated cases.
The 27 patients whose disease was clinically 
confined to the adrenal gland (synchronous in 
14 and metachronous in 13) had statistically 
better survival rates than those with diffuse 

















Fig. 1). Surgical resection of the adrenal 
metastasis led to an apparently curative 
outcome in 10 cases (six with synchronous 
and four with metachronous metastasis) 
showing no relapses at a mean of 
82.9 months after metastasectomy. These 
patients had a renal neoplasm without (seven) 
or with only minimal (three) venous invasion 




The incidence of adrenal metastases from 
RCC is 6–29% [2–5] in autopsy series, but 
from clinical diagnosis is less frequent, at 
2–10% [6–9]. In particular, the involvement 
of the ipsilateral adrenal gland is 19% in 
the autopsy and 5.5% in the surgical series, 
whereas the contralateral adrenal is involved 
in up to 11% of the autopsy series, but with 
slightly fewer than 60 cases reported as of 
2003 [10–12].
In the group of 1179 patients treated for RCC 
in our department, there was an adrenal 
metastasis in 45 (incidence 3.7%). In 
particular, the metastasis was synchronous in 
2.7%, metachronous in 1.0%, ipsilateral in 
1.9%, contralateral in 1.5%, and bilateral in 
0.3% of patients.
During the staging of RCC, CT had a high, 
although not absolute, negative predictive 
value and a low positive predictive value for 
the diagnosis of a pathological (for both 
benign or metastatic) ipsilateral gland: 
remarkably, false-negative results were more 
frequent (four) in the group of 10 patients 
with an isolated unilateral metastasis.
By contrast, there was a high positive 
predictive capability in diagnosing a 
pathological contralateral adrenal gland 
during staging, with only one normal adrenal 
of 15 removed at the same time as surgery for 
renal cancer, and during the follow-up, with 
13 metastases of 14. Furthermore, the 
accuracy of CT for distinguishing between 
benign and malignant contralateral adrenal 
nodules has improved recently, using CT 
protocols to evaluate the wash-out of 
contrast media [13].
Without considering the presence of distant 
metastases and taking into account only loco-
regional staging, synchronous ipsilateral 
metastases were generally associated with 
tumours extending to perirenal tissues, to 
other organs or with lymph node metastases, 
but in two cases there was a small (5 and 
6 cm) neoplasm confined to the renal capsule 
(Table 2). From this evidence we think that an 
adrenal-sparing procedure can be used for 




4 cm, as 
indirectly confirmed by the absence of adrenal 
metastases in the 171 patients who had a 
nephrectomy and adrenalectomy for a 
neoplasm with the same features. Moreover, 
none of the 211 patients treated by surgery 
(nephron-sparing or ablative) with no 
adrenalectomy for similar tumours developed 
an ipsilateral metastasis in the long term. 
Conversely, there were two cases of bilateral 
metachronous metastasis after an adrenal-
sparing nephrectomy for a 6-cm pT3a tumour. 
The lack of involvement of the renal upper 
pole in 19% of cases with ipsilateral 
metastasis, and the incomplete negative 
predictive capability of CT make the 
topographic location of tumour and the 
preoperative ipsilateral adrenal CT findings an 
unreliable base for selecting adrenal-sparing 
surgery during nephrectomy. Adrenalectomy 
could be avoided only during nephrectomy for 




The Kaplan-Meier survival curves for the 27 
patients whose disease was clinically confined to 
the adrenal gland (synchronous in 14 and 

























A N T O N E L L I  
 






 2 0 0 6  B J U  I N T E R N A T I O N A L
 
kidneys, while an adrenal-sparing procedure 




4 cm in diameter is 
inadvisable, even in the presence of a 
contralateral adrenal mass. Notably, all the 





4 cm, and in one case the 
unilateral adrenal was normal on CT.
The incidence of metachronous adrenal 
metastasis was, respectively, 0.4% (three/657) 
and 3.5% (10/285) in stage I and III renal 
tumours, with a wide variability of latency in 
diagnosis (8–73 months); these values 
confirm, as recently reported by others [14], 
that an extended follow-up with CT is more 
meaningful for patients with high-stage renal 
cancer, but also shows how a metastasis can 
develop in stage I disease. The evidence of 
metastatic disease confined to the adrenals in 
all the patients with a metachronous 
metastasis is probably due to the early 
diagnosis, but we usually do not routinely use 
CT, but use abdominal ultrasonography, after 
a 2-year follow-up with no relapses. These 
considerations warrant a long-term follow-
up for all patients with RCC using periodic 
ultrasonography, and suggest the tailored use 
of CT.
Even if reported data [15] show a greater risk 
of adrenal insufficiency in patients with RCC, 
only the 31 patients treated by bilateral 
adrenalectomy (in one or two steps) 
chronically required substitution therapy with 
oral cortisone acetate (25 mg in the morning 
and 12.5 mg in the afternoon) for 
glucocorticoid replacement, while 
mineralocorticoid replacement with oral 
fludrocortisone (0.1–0.3 mg daily) was used 
only in patients who had an imbalance in 
serum electrolytes. There was mostly good 
tolerance to substitution therapy but careful 
adjustments are needed during stressful 
periods to avoid Addisionan crises, as 
happened in one patient who died from this 
cause.
The results for the 27 patients shown in Fig. 1 
suggest the existence of a preferential pattern 
of dissemination to the adrenal gland which 
should outline a ‘limited’, less aggressive, and 
therefore surgically curable metastatic 
disease. However, the relapses experienced by 
the other patients with an isolated adrenal 
metastasis, in principle equally eligible for 
curative surgery, confirm that the true 
extension of neoplastic disease is still widely 
underestimated by the available diagnostic 
tools.
There were no differences in survival between 
patients with synchronous or metachronous 


















 0.685), or between those with a 


















 0.431) even when data 
were adjusted for the extension of metastatic 
disease (isolated or disseminated).
In conclusion, in the present 1179 patients 
with RCC, the incidence of adrenal metastasis 
was 3.7%, synchronous with the renal tumour 
in 2.7% and metachronous in 1.0%. An 
ipsilateral adrenal-sparing procedure is only 





4 cm, whereas the location of cancer and 
the preoperative CT findings cannot fully 
predict the risk of ipsilateral metastasis. Any 
suspicious contralateral adrenal mass should 
be explored because there is a high probability 
of removing a metastasis.
Oncologically, patients with a solitary adrenal 
metastasis (synchronous or metachronous) 
are candidates for adrenal metastasectomy 
given the good rate of freedom from disease 
after surgery and the acceptable survival rates 
when compared with patients who have 
multiple metastases. These results could 
justify the indication for surgical resection of 
adrenal metastasis from RCC but also 
underline the need for an effective systemic 



























Saitoh H, Nakayama M, Nakamura 
K. 
 
Distant metastasis of renal 












Hellsten S, Berge T, Linell F. 
 
Clinically 
unrecognised renal carcinoma: aspects of 
tumor morphology, lymphatic and 












Bennington JL, Kradjian RM. 
 





, Chapt. 10. 




Hajdu SI, Thomas AG. 
 
Renal cell 

















Adrenal metastasis in 1635 patients with 
renal cell carcinoma: outcome and 











Angervall L, Wahlqvist L. 
 
Follow-up and 
prognosis of renal carcinoma in a series 
operated by perifascial nephrectomy 













Robey EL, Schellhammer PF. 
 
The adrenal 
gland and renal cell carcinoma: is 
ipsilateral adrenalectomy a necessary 











Paul R, Mordhorst J, Leyh H, Hartung R. 
 
Incidence and outcome of patients with 











Lau WK, Zincke H, Lohse CM, 
Cheville JC, Weaver AL, Blute ML. 
 
Contralateral adrenal metastasis of 
renal cell carcinoma: treatment, 











Dieckmann KP, Wullbrand A, Kroizig G. 
 
Contralateral adrenal metastasis in renal 
cell cancer. 
 









Kessler OJ, Mukamel E, Weinstein R, 
Gayer E, Konichezky M, Servadio C. 
 
Metachronous renal cell carcinoma 














CT characterisation of 
















 Guidelines for the surveillance 
of localized renal cell carcinoma 













Yokoyama H, Tanake M. 
 
Incidence of 
adrenal involvement and assessing 
adrenal function in patients with 
renal cell carcinoma: is ipsilateral 











Correspondence: Alessandro Antonelli, 
Department of Urology, University of Brescia, 
Brescia, Italy.
e-mail: alxanto@hotmail.com
